Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis

Iñarrairaegui, Mercedes; Thurston, Kenneth G.; Bilbao, J.I.; D’Avola, Delia; Rodríguez, Macarena; Arbizu, Javier; Martínez-Cuesta, Antonio; Sangro, Bruno

doi:10.1016/j.jvir.2010.04.012

Cited by 129 publications

(82 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, there is increasing evidence that TARE can be delivered safely and effectively in suitable HCC patients with PVTT, with several studies reporting median overall survival rates of approximately 10 months following the procedure in these patients (table 3) [36,45,46,47,48,49,50]. Again the extent of PVTT affected survival outcome.…”

Section: Locoregional Strategiesmentioning

confidence: 99%

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

et al. 2013

Self Cite

View full text Add to dashboard Cite

Background/Purpose: Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) have an extremely poor prognosis and relatively few treatment options. Method: During a consensus meeting, experts met to examine the published data for HCC treatment strategies in patients with PVTT. Results: Many treatment guidelines consider the presence of PVTT a contraindication to partial hepatectomy or liver transplantation. Transarterial chemoembolization (TACE) is associated with an increased risk of ischemic necrosis of liver and of treatment-related death in patients with PVTT, and is, therefore, limited to a select group of patients with good hepatic function and adequate collateral circulation around the occluded portal vein. Systemic sorafenib results in survival benefit in patients regardless of the presence of PVTT. However, side effects are common, and there are no effects on time-to-symptom progression or quality of life. Transarterial radioembolization (TARE) with yttrium-90 microspheres is emerging as a valuable strategy. A wider range of patients with PVTT are suitable for this procedure compared to TACE. TARE is as effective as TACE in HCC and has quality-of-life advantages. Conclusion: In patients with HCC with PVTT, medical evidence suggests that TARE is a good choice of treatment.

show abstract

Section: Locoregional Strategiesmentioning

confidence: 99%

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sub-group analyses revealed that TTP in the absence of portal vein thrombosis was 15.5 mo while TTP in the presence of portal vein thrombosis was 5.6 mo, suggesting that treatment with 90Y glass microspheres could represent an effective option, especially in patients with portal vein thrombosis for whom TACE is conventionally not thought suitable. Several other studies have also reported favorable results in advanced HCC [107][108][109] . However, major bodies worldwide have recommended further RCTs to evaluate the safety and efficacy of 90Y [110] .…”

Section: Advanced-stage Hccmentioning

confidence: 83%

Locoregional treatment for hepatocellular carcinoma: The best is yet to come

Kalra

Gupta

Chawla

et al. 2015

WJR

View full text Add to dashboard Cite

“…In patients with advanced BCLC stage, Y90-RE treatment has superior results compared with trans-arterial chemo embolization (TACE) (32). Y90-RE was first of all described as an alternative option for non-resectable liver tumors (7,21,(33)(34)(35). Accordingly in selected patients, Y90-RE is considered an effective tool for the downstaging strategy (36,37).…”

Section: Discussionmentioning

confidence: 99%

Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review

Sandri

Ettorre

Giannelli

et al. 2017

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Liver transplantation (LT) for hepatocellular carcinoma (HCC) within the Milan criteria (MC)is nowadays a curative procedure. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. The aim of this work is to offer a view on the publications which report on the use of Y90-RE as bridge or downstaging prior to LT. Twenty articles have been considered for this world review. About 178 LT in patients were treated with Y90-RE prior to LT. Most of patients had a downstaging strategy. In all series alpha-fetoproteins decreased between Y90-RE and LT.Therefore, Y90-RE may have an important role in the bridge and downstaging treatments.

show abstract

Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis

Cited by 129 publications

References 26 publications

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

Locoregional treatment for hepatocellular carcinoma: The best is yet to come

Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review

Contact Info

Product

Resources

About